HK1052179A1 - 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑 - Google Patents

作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑 Download PDF

Info

Publication number
HK1052179A1
HK1052179A1 HK03104436.1A HK03104436A HK1052179A1 HK 1052179 A1 HK1052179 A1 HK 1052179A1 HK 03104436 A HK03104436 A HK 03104436A HK 1052179 A1 HK1052179 A1 HK 1052179A1
Authority
HK
Hong Kong
Prior art keywords
agonists
antagonists
substituted imidazoles
dual histamine
methods
Prior art date
Application number
HK03104436.1A
Other languages
English (en)
Chinese (zh)
Inventor
Shih Neng-Yang
M. Solomon Daniel
J. Piwinski John
T. Lupo Andrew Jr.
J. Green Michael
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK1052179A1 publication Critical patent/HK1052179A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03104436.1A 2000-09-20 2001-09-18 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑 HK1052179A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23405300P 2000-09-20 2000-09-20
US60/234,053 2000-09-20
PCT/US2001/029095 WO2002024659A2 (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists

Publications (1)

Publication Number Publication Date
HK1052179A1 true HK1052179A1 (zh) 2003-09-05

Family

ID=22879692

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104436.1A HK1052179A1 (zh) 2000-09-20 2001-09-18 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑

Country Status (15)

Country Link
US (1) US6506756B2 (enExample)
EP (1) EP1318994B1 (enExample)
JP (1) JP2004509871A (enExample)
CN (1) CN1461303A (enExample)
AR (1) AR030946A1 (enExample)
AT (1) ATE387439T1 (enExample)
AU (1) AU2001292730A1 (enExample)
CA (1) CA2421826C (enExample)
DE (1) DE60133014T2 (enExample)
ES (1) ES2300364T3 (enExample)
HK (1) HK1052179A1 (enExample)
MX (1) MXPA03002448A (enExample)
MY (1) MY117975A (enExample)
TW (1) TW589303B (enExample)
WO (1) WO2002024659A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607862B2 (en) 2001-08-24 2003-08-19 Intel Corporation Damascene extreme ultraviolet lithography alternative phase shift photomask and method of making
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
EP1499316B1 (en) * 2002-04-18 2008-03-19 Schering Corporation (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists
WO2003103669A1 (en) * 2002-04-18 2003-12-18 Schering Corporation 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists
NL1026634C2 (nl) * 2004-07-12 2006-01-16 Willem Jacob Van Der Burg Psychofarmaceutisch preparaat en werkzame stof daarin.
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9224955B1 (en) * 2014-10-31 2015-12-29 Feng-wen Yen Purifying method for organic optoelectronic material
CN113880808B (zh) * 2020-07-03 2024-12-31 合肥医工医药股份有限公司 一类三唑类化合物、制备方法及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
ZA893104B (en) * 1988-04-28 1989-12-27 Schering Corp Novel benzopyrido piperidine,piperidylidene and piperazine compounds,compositions,methods of manufacture and methods of use
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
DK0448765T3 (da) 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
WO1993012093A1 (en) 1991-12-18 1993-06-24 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
NZ330898A (en) 1993-11-15 2000-01-28 Schering Corp Phenyl-alkyl imidazoles as H3-receptor antagonists in particular for the treatment of inflammation
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT1019050E (pt) 1997-06-24 2002-09-30 Novo Nordisk As Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
AU4387699A (en) 1998-07-24 2000-02-14 Russinsky Limited A process for preparing benzocycloheptapyridin-11-ones

Also Published As

Publication number Publication date
DE60133014D1 (de) 2008-04-10
CA2421826A1 (en) 2002-03-28
EP1318994A2 (en) 2003-06-18
CN1461303A (zh) 2003-12-10
ATE387439T1 (de) 2008-03-15
US6506756B2 (en) 2003-01-14
CA2421826C (en) 2009-10-27
ES2300364T3 (es) 2008-06-16
DE60133014T2 (de) 2009-02-26
JP2004509871A (ja) 2004-04-02
MY117975A (en) 2004-08-30
AR030946A1 (es) 2003-09-03
AU2001292730A1 (en) 2002-04-02
MXPA03002448A (es) 2003-06-19
WO2002024659A2 (en) 2002-03-28
EP1318994B1 (en) 2008-02-27
US20020086859A1 (en) 2002-07-04
WO2002024659A3 (en) 2002-10-24
TW589303B (en) 2004-06-01

Similar Documents

Publication Publication Date Title
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
YU42402A (sh) Jedinjenja karbamida koja imaju antagonističku aktivnost na muskarinski receptor
WO2004082602A3 (en) Carboxamide spirohydantoin cgrp receptor antagonists
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2004082605A3 (en) Bicyclic anilide spirohydantoin cgrp receptor antagonists
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
MXPA02005596A (es) Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
WO2007126935A3 (en) Diazepan orexin receptor antagonists
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
WO2008008517A3 (en) Bridged diazepan orexin receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2004005262A3 (en) New neuropeptide y y5 receptor antagonists
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
AU1092800A (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
WO2002044141A3 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
HK1052179A1 (zh) 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑